Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)
Why Analysts Believe This Small Ocular Concern Can Double
This week’s free report is on a small ocular concern that has a very favorable risk/reward outlook at current trading levels. The company also has a few “shots on goal,” upcoming near term catalysts and increasingly positive analyst support. Plus
